New evidence suggests that children on ADHD medication may have stunted growth initially but more rapid increases in body mass over time.
A recent article in the American Journal of Public Health calls for policy level interventions to reduce the use of benzodiazepines, drugs commonly prescribed...
Medically-induced harm—affecting tens of millions of people worldwide—has taken the field decades to take seriously.
Despite their finding, the researchers suggest that SSRIs be given to people who do not meet criteria for depression or anxiety.
Ethnographic research sheds light on extensive psychopharmaceutical use by soldiers in post 9/11 U.S. wars.
A new study, published in the journal Molecular Psychiatry, found no link between genetics and the occurrence of depressive symptoms.
A new study suggests that depressive symptoms in older adults can be improved with non-invasive behavioral activation techniques. These approaches appear to have a preventative effect, serving to prevent further depressive symptoms from developing.
Clinical trials also consistently fail to measure and report long-term harmful effects.
A systematic review of the limited research available on the long-term effects of antipsychotics finds fewer symptoms in those off of the drugs.
A common practice when antipsychotics are found to be ineffective for schizophrenia is to prescribe a second, additional psychoactive medication. Now, a new study suggests that this practice is not supported by the research.
“Politicians and Experts Meet at Parliament to Explore Record Antidepressant Prescribing and Disability”
The All-Party Parliamentary Group for Prescribed Drug Dependence is meeting today, May 11th, to discuss evidence of the link between the rise in disability...
“This research points to the inadequacy of asking the simple question: ‘Do antidepressants work?’ Instead, the value or otherwise of antidepressants needs to be understood in the context of the diversity of experience and the particular meaning they hold in people’s lives.”
Between 2007 and 2016, the FDA identified 776 herbal supplements containing active, unapproved pharmaceutical chemicals.
There is accumulating evidence that taking SSRI antidepressants increases the risk of bleeding and other complications during surgery, according to a review published in the British Journal of Anaesthesia.
Following an extensive systematic review of treatments for major depression, the American College of Physicians (ACP) issued a recommendation to clinicians suggesting cognitive behavioral therapy (CBT) as a first-line treatment for major depressive disorder along with second-generation antidepressants. The results of the review revealed that CBT and antidepressants have similar levels of effectiveness but that antidepressants present serious side-effects and higher relapse rates.
A California jury ruled that Johnson & Johnson’s Janssen Pharmaceutical and a psychiatrist were responsible for the death of 25-year-old Leo Liu. During a clinical trial for Risperdal, Liu died of a heart injury that was “further complicated” by the drug and ignored by the study doctors. Janssen was found 70% responsible for Liu’s death and ordered to pay $5.6 million to the family.
Gepirone, a new depression drug by Fabre-Kramer Pharmaceuticals, did not meet the FDAs efficacy standards. The new drug application for gepirone has now received...
Antipsychotics are currently the predominant treatment for individuals diagnosed with schizophrenia, but there is an accumulating body of research that links the use of these drugs to structural abnormalities in the brain. A recent meta-analysis suggests that gray matter loss in the brain may depend on the dose and class of the antipsychotic.
Researchers believe that side-effect monitoring is critical because of the increase in the use of antipsychotics
Researchers identify simple ways for clinicians to begin deprescribing conversations.
In 2004, the American Psychiatric Association published a paper supporting the use of the antidepressant citalopram (Celexa) in children and teens. After reanalyzing the...
More than one-in-10 forms authorising ECT received by the Mental Health Commission (MHC) between 2013 and 2015 reported that the patient was unwilling to consent...
A systematic review of literature and meta-analysis indicates that there is no clinically or statistically significant effect of antidepressant dose increase after nonresponse to initial treatment.
Instead of reducing risk, the dose reduction recommendation made by the FDA in their safety message was associated with an increase in hospitalizations.
Four different studies conducted in different ways examining different groups have linked use of certain psychiatric drugs to bone fracture risks and negative impacts on human bone development.